Biohaven presents three posters at ATA, highlighting the patient experience, autoimmune biology of disease, and MoDE and TRAP platform, reflecting a research program built around a condition that remains strikingly
The US Food and Drug Administration (FDA) accepted new drug application resubmission for Vyglxia (troriluzole) in spinocerebeller ataxia (SCA), user fee goal date 1Q27. Announced exclusive global license with SK
One year after Biohaven's first TRAP degrader, BHV-1400, was highlighted in the Kidney Week opening plenary, Biohaven's second TRAP degrader for kidney disease expands its Yale-licensed platform into a growing
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a
Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trialsNEW YORK, Sept. 11, 2026
SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of
NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE:BHVN) and Yale University ("Yale") today announced that the U.S. District Court for
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underwayPositive clinical biomarker and
Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to Biohaven as the company advances AI-enabled approaches to drug developmentNEW HAVEN, Conn., Aug. 6, 2026 /PRNewswire/ --
NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE:BHVN) and Yale University ("Yale") today announced that a federal jury in the U.S.
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)Early clinical activity observed: Phase 1 dose-escalation data show early tumor
David Pirman, Ph.D. promoted to Executive Vice President and Head of DiscoveryBruce Car, Ph.D. transitioning from Chief Scientific Officer to new role as Chief Innovation Officer focusing on external
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root of autoimmune
